{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:52:55Z","timestamp":1787025175971,"version":"build-2736575974"},"reference-count":50,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":2634,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:p>Increased pancreas mass and glucagon-positive adenomas have been suggested to be a risk associated with sitagliptin or exenatide therapy in humans. Novo Nordisk has conducted extensive toxicology studies, including data on pancreas weight and histology, in Cynomolgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists. In a 52-week study with liraglutide, a dose-related increase in absolute pancreas weight was observed in female monkeys only. Such dose-related increase was not found in studies of 4, 13, or 87 weeks\u2019 duration. No treatment-related histopathological abnormalities were observed in any of the studies. Quantitative histology of the pancreas from the 52-week study showed an increase in the exocrine cell mass in liraglutide-dosed animals, with normal composition of endocrine and exocrine cellular compartments. Proliferation rate of the exocrine tissue was low and comparable between groups. Endocrine cell mass and proliferation rates were unaltered by liraglutide treatment. Semaglutide showed no increase in pancreas weight and no treatment-related histopathological findings in the pancreas after 13 or 52 weeks\u2019 dosing. Overall, results in 138 nonhuman primates showed no histopathological changes in the pancreas associated with liraglutide or semaglutide, two structurally different GLP-1 receptor agonists.<\/jats:p>","DOI":"10.2337\/db13-1087","type":"journal-article","created":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T00:43:49Z","timestamp":1394239429000},"page":"2486-2497","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":50,"title":["The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates"],"prefix":"10.2337","volume":"63","author":[{"given":"Carsten F.","family":"Gotfredsen","sequence":"first","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"M\u00f8lck","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Thorup","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels C. Berg","family":"Nyborg","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"Salanti","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte Bjerre","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne O.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Diabetes Research Unit, Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,6,14]]},"reference":[{"key":"2022031223304191900_B1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol Ther"},{"key":"2022031223304191900_B2"},{"key":"2022031223304191900_B3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1172\/JCI42497","article-title":"Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice","volume":"122","author":"Lamont","year":"2012","journal-title":"J Clin Invest"},{"key":"2022031223304191900_B4","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1172\/JCI43615","article-title":"Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis","volume":"121","author":"Ali","year":"2011","journal-title":"J Clin Invest"},{"key":"2022031223304191900_B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2014role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"2022031223304191900_B6","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223304191900_B7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1463-1326.2009.01167.x","article-title":"Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus","volume":"12","author":"Aaboe","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2022031223304191900_B8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials","volume":"96","author":"Buse","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223304191900_B9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","article-title":"Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031223304191900_B10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2337\/dc12-0709","article-title":"The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031223304191900_B11","first-page":"S7","article-title":"The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes","volume":"55","author":"Nauck","year":"2012","journal-title":"Diabetologia"},{"key":"2022031223304191900_B12","unstructured":"World Health Organization. WHO guidelines on the quality, safety, and efficacy of biotherapeutic products prepared by recombinant DNA technology. Available from http:\/\/www.who.int\/biologicals\/WHO_rDNA_2nd_public_consultation_28_June_2013.pdf. Accessed 14 Oct 2013"},{"key":"2022031223304191900_B13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/db11-0936","article-title":"The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species","volume":"61","author":"Nyborg","year":"2012","journal-title":"Diabetes"},{"key":"2022031223304191900_B14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"key":"2022031223304191900_B15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"2022031223304191900_B16","doi-asserted-by":"crossref","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"2022031223304191900_B17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1078\/0940-2993-00311","article-title":"Revised guides for organ sampling and trimming in rats and mice\u2014part 1","volume":"55","author":"Ruehl-Fehlert","year":"2003","journal-title":"Exp Toxicol Pathol"},{"key":"2022031223304191900_B18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/01926230490268756","article-title":"Best practices guideline: toxicologic histopathology","volume":"32","author":"Crissman","year":"2004","journal-title":"Toxicol Pathol"},{"key":"2022031223304191900_B19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1699-0463.1999.tb01474.x","article-title":"Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas","volume":"107","author":"Bock","year":"1999","journal-title":"APMIS"},{"key":"2022031223304191900_B20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2818.2002.01054.x","article-title":"The smooth fractionator","volume":"207","author":"Gundersen","year":"2002","journal-title":"J Microsc"},{"key":"2022031223304191900_B21","doi-asserted-by":"crossref","first-page":"E1342","DOI":"10.1152\/ajpendo.00564.2001","article-title":"Mild streptozotocin diabetes in the G\u00f6ttingen minipig. A novel model of moderate insulin deficiency and diabetes","volume":"282","author":"Larsen","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031223304191900_B22","unstructured":"Novo Nordisk: Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341. Available from http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm148659.pdf. Accessed 11 July 2013"},{"key":"2022031223304191900_B23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.diabres.2009.06.021","article-title":"No mantle formation in rodent islets\u2014the prototype of islet revisited","volume":"85","author":"Kharouta","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031223304191900_B24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/0192623310385141","article-title":"Choice of morphometric methods and consequences in the regulatory environment","volume":"38","author":"Boyce","year":"2010","journal-title":"Toxicol Pathol"},{"key":"2022031223304191900_B25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"2022031223304191900_B26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"key":"2022031223304191900_B27","doi-asserted-by":"crossref","first-page":"E2109","DOI":"10.1210\/jc.2012-1815","article-title":"Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes","volume":"97","author":"Williams","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223304191900_B28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1098-108X(200004)27:3<297::AID-EAT6>3.0.CO;2-6","article-title":"Interrelationships between the size of the pancreas and the weight of patients with eating disorders","volume":"27","author":"Cuntz","year":"2000","journal-title":"Int J Eat Disord"},{"key":"2022031223304191900_B29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.2337\/db13-0520","article-title":"Incretin therapy and islet pathology: a time for caution","volume":"62","author":"Kahn","year":"2013","journal-title":"Diabetes"},{"key":"2022031223304191900_B30","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.2337\/db13-0822","article-title":"Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls","volume":"62","author":"Drucker","year":"2013","journal-title":"Diabetes"},{"key":"2022031223304191900_B31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/diab.31.8.694","article-title":"Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans","volume":"31","author":"Stefan","year":"1982","journal-title":"Diabetes"},{"key":"2022031223304191900_B32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF00251826","article-title":"Cellular composition of the human diabetic pancreas","volume":"24","author":"Rahier","year":"1983","journal-title":"Diabetologia"},{"key":"2022031223304191900_B33","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.2337\/diabetes.53.12.3107","article-title":"Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome","volume":"53","author":"Street","year":"2004","journal-title":"Diabetes"},{"key":"2022031223304191900_B34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0940-2993(98)80078-X","article-title":"A comparative immunohistochemical study of pancreatic islets in laboratory animals (rats, dogs, minipigs, nonhuman primates)","volume":"50","author":"Wieczorek","year":"1998","journal-title":"Exp Toxicol Pathol"},{"key":"2022031223304191900_B35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/isl.1.2.9480","article-title":"Islet architecture: A comparative study","volume":"1","author":"Kim","year":"2009","journal-title":"Islets"},{"key":"2022031223304191900_B36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4161\/isl.2.3.11815","article-title":"Pancreatic islet plasticity: interspecies comparison of islet architecture and composition","volume":"2","author":"Steiner","year":"2010","journal-title":"Islets"},{"key":"2022031223304191900_B37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1600-0463.2003.apm1111207.x","article-title":"The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211","volume":"111","author":"Bock","year":"2003","journal-title":"APMIS"},{"key":"2022031223304191900_B38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/db06-0565","article-title":"Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not","volume":"56","author":"Raun","year":"2007","journal-title":"Diabetes"},{"key":"2022031223304191900_B39","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/db09-1564","article-title":"Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats","volume":"59","author":"Cummings","year":"2010","journal-title":"Diabetes"},{"key":"2022031223304191900_B40","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00182.2012","article-title":"The effects of 13 weeks of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF-rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis","author":"Vrang","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031223304191900_B41","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1152\/ajpendo.00025.2013","article-title":"One year of sitagliptin treatment protects against islet amyloid-associated \u03b2-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice","volume":"305","author":"Aston-Mourney","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031223304191900_B42"},{"key":"2022031223304191900_B43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology"},{"key":"2022031223304191900_B44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/en.2012-2124","article-title":"The glucagon-like peptide-1 receptor\u2014or not?","volume":"154","author":"Pyke","year":"2013","journal-title":"Endocrinology"},{"key":"2022031223304191900_B45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00210-009-0395-y","article-title":"How reliable are G-protein-coupled receptor antibodies?","volume":"379","author":"Michel","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022031223304191900_B46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00210-009-0393-0","article-title":"Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors","volume":"379","author":"Pradidarcheep","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022031223304191900_B47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00210-009-0392-1","article-title":"Lack of specificity of antibodies directed against human beta-adrenergic receptors","volume":"379","author":"Hamdani","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022031223304191900_B48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1210\/en.2012-2222","article-title":"Editorial: antibody validation requirements for articles published in endocrinology","volume":"154","author":"Gore","year":"2013","journal-title":"Endocrinology"},{"key":"2022031223304191900_B49","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J Nucl Med"},{"key":"2022031223304191900_B50","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas","volume":"52","author":"Wild","year":"2011","journal-title":"J Nucl Med"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/63\/7\/2486\/579508\/2486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/63\/7\/2486\/579508\/2486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:38:07Z","timestamp":1667392687000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/63\/7\/2486\/34421\/The-Human-GLP-1-Analogs-Liraglutide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,14]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,6,14]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-1087","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,14]]}}}